JANEWAY LAB Pediatric Oncology Genomics, Precision, Bone Sarcomas
“Leveraging genomics to improve clinical care and trial design for pediatric sarcomas”
The Janeway Lab focuses on genomics, precision oncology, and bone sarcomas. Our work has uncovered the genomic events causing and sustaining difficult-to-treat childhood solid malignancies. Dr. Janeway has leveraged this understanding to expand treatment opportunities and improve clinical trials for children and young adults. We lead the 12-institution iCat2/GAIN consortium study, which has enrolled and sequenced more than 700 patients with rare, difficult-to-treat childhood solid cancers. As part of the National Cancer Institute’s Childhood Cancer Data Initiative, our group is also contributing to efforts to share and aggregate both sequencing and clinical data to enable a deeper understanding of clinicogenomic factors that explain prognosis and treatment response and resistance in childhood cancers. In collaboration with the Broad Institute and Count Me In, the group is innovating patient partnerships in sarcoma research.